AGXT
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
WB 1:500-1:2000
Restrictions
For Research Use only
Concentration
0.6 mg/mL
Buffer
PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Store at -20°C. Avoid freeze / thaw cycles.
Target
AGXT
(Alanine Glyoxylate Aminotransferase (AGXT))
Alternative Name
AGXT
Background
AGT,AGT1,Agxt,AGXT1,Alanine glyoxylate aminotransferase,Alanine glyoxylate aminotransferase3,Alanine--glyoxylate aminotransferase,EC 2.6.1.44,EC 2.6.1.51,Hepatic peroxisomal alanine glyoxylate aminotransferase,Hepatic peroxisomal alanine:glyoxylate aminotransferase,L alanine glyoxylate aminotransferase 1,MS773,PH1,Serine pyruvate aminotransferase,Serine--pyruvate aminotransferase,Serine--pyruvate aminotransferase,mitochondrial,Serine:pyruvate aminotransferase,SPAT,SPT,SPYA,TLH6,Serine-pyruvate aminotransferase is an enzyme that in humans is encoded by the AGXT gene. This gene is expressed only in the liver and the encoded protein is localized mostly in the peroxisomes, where it is involved in glyoxylate detoxification. Mutations in this gene, some of which alter subcellular targetting, have been associated with type I primary hyperoxaluria. Defects in AGXT are the cause of hyperoxaluria primary type 1 (HP1), also known as primary hyperoxaluria type I (PH1) and oxalosis I. HP1 is a rare autosomal recessive inborn error of glyoxylate metabolism characterized by increased excretion of oxalate and glycolate, and the progressive accumulation of insoluble calcium oxalate in the kidney and urinary tract.